By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nektar Therapeutics (CA) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


SEARCH JOBS

Nektar Therapeutics has a robust R&D pipeline and portfolio of approved partnered medicines in oncology, pain, immunology and other therapeutic areas. In the area of oncology, Nektar is developing NKTR-214, an immuno-stimulatory CD122-biased agonist, which is in Phase 1/2 clinical development for patients with solid tumors. ONZEALD™ (etirinotecan pegol), a long-acting topoisomerase I inhibitor, is being developed for patients with advanced breast cancer and brain metastases and is partnered with Daiichi Sankyo in Europe. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™ (naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The product is also approved in the European Union as MOVENTIG® (naloxegol) and is indicated for adult patients with OIC who have had an inadequate response to laxatives. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly owned mu-opioid analgesic molecule for chronic pain conditions, is in Phase 3 development. In hemophilia, Nektar has a collaboration agreement with Baxalta for ADYNOVATE™ [Antihemophilic Factor (Recombinant)], a longer-acting PEGylated Factor VIII therapeutic approved in the U.S. andJapan for patients over 12 with hemophilia A. In anti-infectives, the company has two collaborations with Bayer Healthcare, Cipro Inhale in Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale in Phase 3 for patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.


Key Statistics


Email: nektarSF@nektar.com
Ownership: Public

Web Site: Nektar Therapeutics
Employees: 454
Symbol: NKTR
 









Company News
Nektar Therapeutics (NKTR) Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting 11/10/2016 4:37:56 PM
Nektar Therapeutics (NKTR) Reports Financial Results For The Third Quarter Of 2016 11/4/2016 8:48:46 AM
Nektar Therapeutics (NKTR) To Announce Financial Results For The Third Quarter 2016 On Thursday, November 3, 2016, After Close Of U.S.-Based Financial Markets 10/28/2016 10:59:30 AM
Nektar Therapeutics (NKTR) Prices Public Offering Of Shares Of Common Stock 10/19/2016 7:30:51 AM
Nektar Therapeutics (NKTR) Announces Public Offering Of Shares Of Common Stock 10/18/2016 7:55:43 AM
Bristol-Myers Squibb (BMY) And Nektar Therapeutics (NKTR) Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo(Nivolumab) And NKTR-214 9/27/2016 11:07:34 AM
Nektar Therapeutics (NKTR) To Host Investor & Analyst Conference Call To Discuss New Clinical Collaboration With Bristol-Myers Squibb (BMY) 9/27/2016 10:06:30 AM
Juno (JUNO), Nektar Therapeutics (NKTR) CEOs Sold $1 Million of Stock Before Labor Day 9/9/2016 6:04:31 AM
Nektar Therapeutics (NKTR) Reports Financial Results For The Second Quarter Of 2016 8/4/2016 7:56:45 AM
Nektar Therapeutics (NKTR) To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets 7/28/2016 8:51:59 AM
12345678910...
//-->